Jingxuan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingxuan Wang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Liqian Su
Precision Medicine Center, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
3 shared publicationsShichao Wen
Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
3 shared publicationsQi Liu
Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
2 shared publications- Qingyuan Zhang
Department of Breast & Lymphoma, Harbin Medical University Cancer Hospital, Harbin, China
2 shared publications Yiqiu Ma
Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
2 shared publicationsYuhan Liu
Department of Medical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150081, China
2 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer
Background: Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown encouraging clinical efficacy in breast cancer, primarily by modulating the tumor microenvironment (TME). However, achieving durable clinical responses remains a major challenge. Although the deubiquitinating enzyme 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) is known to exert oncogenic functions in various cancers, its potential role in regulating tumor immune evasion remains unclear. This study investigates how PSMD14 regulates PD-L1 and reshapes the TME, with the goal of clarifying its impact on immune regulation in breast cancer. Methods: PSMD14 expression and its prognostic significance in breast cancer were analyzed using public databases and clinical samples. The correlation between PSMD14 and PD-L1 was validated by immunohistochemistry (IHC), western blot, and flow cytometry. The mechanism by which PSMD14 stabilizes PD-L1 through deubiquitination and their interaction was investigated using cycloheximide chase assays, co-immunoprecipitation (Co-IP), and ubiquitination assays. The impact of PSMD14 on the TME and its influence on immunotherapy efficacy were evaluated using T cell cytotoxicity assays, syngeneic mouse models, and flow cytometry analyses. Results: PSMD14 was highly expressed in breast cancer and correlated with poor patient prognosis. Mechanistically, PSMD14 stabilized PD-L1 by interacting with its intracellular domain and removing its K48-linked polyubiquitin chains, thereby inhibiting proteasomal degradation. Inhibition of PSMD14 enhanced antigen presentation and CD8⁺ T cell activation, reduced the accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and altered macrophage polarization. These changes collectively improved the response to immunotherapy in breast cancer. Conclusion: This study identifies PSMD14 as a critical regulator of immune responses in breast cancer. Targeting PSMD14 enhances the effectiveness of immunotherapy by promoting PD-L1 degradation and remodeling the TME, offering a potential strategy to improve clinical outcomes.
- 14 April 2026
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 45 (1)
Open AccessTargeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer
Background: Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown encouraging clinical efficacy in breast cancer, primarily by modulating the tumor microenvironment (TME). However, achieving durable clinical responses remains a major challenge. Although the deubiquitinating enzyme 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) is known to exert oncogenic functions in various cancers, its potential role in regulating tumor immune evasion remains unclear. This study investigates how PSMD14 regulates PD-L1 and reshapes the TME, with the goal of clarifying its impact on immune regulation in breast cancer. Methods: PSMD14 expression and its prognostic significance in breast cancer were analyzed using public databases and clinical samples. The correlation between PSMD14 and PD-L1 was validated by immunohistochemistry (IHC), western blot, and flow cytometry. The mechanism by which PSMD14 stabilizes PD-L1 through deubiquitination and their interaction was investigated using cycloheximide chase assays, co-immunoprecipitation (Co-IP), and ubiquitination assays. The impact of PSMD14 on the TME and its influence on immunotherapy efficacy were evaluated using T cell cytotoxicity assays, syngeneic mouse models, and flow cytometry analyses. Results: PSMD14 was highly expressed in breast cancer and correlated with poor patient prognosis. Mechanistically, PSMD14 stabilized PD-L1 by interacting with its intracellular domain and removing its K48-linked polyubiquitin chains, thereby inhibiting proteasomal degradation. Inhibition of PSMD14 enhanced antigen presentation and CD8⁺ T cell activation, reduced the accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and altered macrophage polarization. These changes collectively improved the response to immunotherapy in breast cancer. Conclusion: This study identifies PSMD14 as a critical regulator of immune responses in breast cancer. Targeting PSMD14 enhances the effectiveness of immunotherapy by promoting PD-L1 degradation and remodeling the TME, offering a potential strategy to improve clinical outcomes.
- 31 January 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127832
Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis
- 31 January 2026
- Published by Elsevier in Journal of Trace Elements in Medicine and Biology
- Vol. 94, 127832
Comprehensive bioinformatic analysis and experimental validation identify MT1M and MT1X as key metallothioneins in BC pathogenesis
- 1 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 327, 147275
PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway
- 1 September 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 327, 147275
PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway
- Open Access
- 17 March 2025
- Published by Wiley in Cancer Science
- Vol. 116 (6) , 1565-1578
Lnc‐TPT1‐AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression
The purine biosynthetic pathway was recently identified to play a crucial role in breast cancer progression. However, little was known about the regulatory mechanisms of long non‐coding RNA in breast cancer purine metabolism. In this study, we discovered that LncRNA TPT1‐AS1 (TPT1‐AS1) was downregulated in breast cancer tissues. Its introduction in breast cancer cells markedly suppressed tumor growth and metastasis in xenograft tumor models. Mass spectrometric analysis suggested that the purine biosynthetic pathway was activated in TPT1‐AS1‐knockdown MCF‐7 cells. Inosine monophosphate (IMP), the product of de novo purine biosynthesis, was significantly upregulated. Mechanistically, we found that TPT1‐AS1 could physically interact with CBP (CREB‐binding protein), which consequently led to the loss of H3K27Ac in the promoter area of ATIC, the key enzyme of IMP synthesis. This process could block breast cancer purine metabolism and inhibit breast cancer progression. In conclusion, our findings illustrate the role of non‐coding RNAs in breast cancer purine metabolism reprogramming and present a potential candidate for breast cancer therapy.
- 17 March 2025
- Published by Wiley in Cancer Science
- Vol. 116 (6) , 1565-1578
Open AccessLnc‐TPT1‐AS1/CBP/ATIC Axis Mediated Purine Metabolism Activation Promotes Breast Cancer Progression
The purine biosynthetic pathway was recently identified to play a crucial role in breast cancer progression. However, little was known about the regulatory mechanisms of long non‐coding RNA in breast cancer purine metabolism. In this study, we discovered that LncRNA TPT1‐AS1 (TPT1‐AS1) was downregulated in breast cancer tissues. Its introduction in breast cancer cells markedly suppressed tumor growth and metastasis in xenograft tumor models. Mass spectrometric analysis suggested that the purine biosynthetic pathway was activated in TPT1‐AS1‐knockdown MCF‐7 cells. Inosine monophosphate (IMP), the product of de novo purine biosynthesis, was significantly upregulated. Mechanistically, we found that TPT1‐AS1 could physically interact with CBP (CREB‐binding protein), which consequently led to the loss of H3K27Ac in the promoter area of ATIC, the key enzyme of IMP synthesis. This process could block breast cancer purine metabolism and inhibit breast cancer progression. In conclusion, our findings illustrate the role of non‐coding RNAs in breast cancer purine metabolism reprogramming and present a potential candidate for breast cancer therapy.
- Open Access
- 23 March 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (2) , 1325-1337
Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and other adverse outcomes. Methods: We retrospectively analyzed 201 DLBCL patients who underwent pre-treatment abdominal CT examination. CT images were used to assess body composition metrics at the third lumbar vertebrae including fat tissues and muscle. Based on the skeletal muscle area (SMA) and density (SMD), skeletal muscle index (SMI), skeletal muscle gauge (SMG = SMI × SMD) and lean body mass (LBM) were calculated. Also analyzed were the toxicity, adverse events and survival. Results: We found that SMG, SMD, SMI and LBM were correlated with any grade 3–4 toxicity, dose reduction, hospitalization or termination of the treatment due to immunochemotherapy and worse survival. However, multivariate analysis demonstrated SMG [progression-free survival (PFS): hazard ratio (HR), 2.889; 95% CI, 1.401–5.959; p = 0.004; overall survival (OS): HR, 2.655; 95% CI, 1.218–5.787; p = 0.014] was the best predictor of poor prognosis. Conclusions: SMG, SMD, SMI and LBM were identified as predictors of adverse reactions and poor survival. SMG was an innovative and valuable indicator of immunochemotherapy toxicity and other adverse outcomes. Additionally, it can be used to individualize antineoplastic drug dosing.
- 23 March 2021
- Published by MDPI AG in Current Oncology
- Vol. 28 (2) , 1325-1337
Open AccessBody Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
Background: Our study measured the body composition of Diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab with cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) regimen by computed tomographic (CT) and assessed their correlation with treatment-related toxicity and other adverse outcomes. Methods: We retrospectively analyzed 201 DLBCL patients who underwent pre-treatment abdominal CT examination. CT images were used to assess body composition metrics at the third lumbar vertebrae including fat tissues and muscle. Based on the skeletal muscle area (SMA) and density (SMD), skeletal muscle index (SMI), skeletal muscle gauge (SMG = SMI × SMD) and lean body mass (LBM) were calculated. Also analyzed were the toxicity, adverse events and survival. Results: We found that SMG, SMD, SMI and LBM were correlated with any grade 3–4 toxicity, dose reduction, hospitalization or termination of the treatment due to immunochemotherapy and worse survival. However, multivariate analysis demonstrated SMG [progression-free survival (PFS): hazard ratio (HR), 2.889; 95% CI, 1.401–5.959; p = 0.004; overall survival (OS): HR, 2.655; 95% CI, 1.218–5.787; p = 0.014] was the best predictor of poor prognosis. Conclusions: SMG, SMD, SMI and LBM were identified as predictors of adverse reactions and poor survival. SMG was an innovative and valuable indicator of immunochemotherapy toxicity and other adverse outcomes. Additionally, it can be used to individualize antineoplastic drug dosing.